These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 38239267)
1. Recent Developments in Selective Agonists and Antagonists Acting at Purine and Pyrimidine Receptors. Jacobson KA; Suzuki F Drug Dev Res; 1996; 39(3-4):289-300. PubMed ID: 38239267 [TBL] [Abstract][Full Text] [Related]
2. The role of the adenosinergic system in lung fibrosis. Della Latta V; Cabiati M; Rocchiccioli S; Del Ry S; Morales MA Pharmacol Res; 2013 Oct; 76():182-9. PubMed ID: 23994158 [TBL] [Abstract][Full Text] [Related]
3. A Jacobson KA; Moro S; Kim YC; Li AH Drug Dev Res; 1998; 45(3-4):113-124. PubMed ID: 31808655 [TBL] [Abstract][Full Text] [Related]
4. Functional expression of adenosine A2A and A3 receptors in the mouse dendritic cell line XS-106. Dickenson JM; Reeder S; Rees B; Alexander S; Kendall D Eur J Pharmacol; 2003 Aug; 474(1):43-51. PubMed ID: 12909194 [TBL] [Abstract][Full Text] [Related]
5. Cardioprotection induced by adenosine A1 receptor agonists in a cardiac cell ischemia model involves cooperative activation of adenosine A2A and A2B receptors by endogenous adenosine. Urmaliya VB; Church JE; Coupar IM; Rose'Meyer RB; Pouton CW; White PJ J Cardiovasc Pharmacol; 2009 May; 53(5):424-33. PubMed ID: 19333129 [TBL] [Abstract][Full Text] [Related]
6. Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBA/2 mice. De Sarro G; De Sarro A; Di Paola ED; Bertorelli R Eur J Pharmacol; 1999 Apr; 371(2-3):137-45. PubMed ID: 10357250 [TBL] [Abstract][Full Text] [Related]
7. Purinergic modulation of glutamate release under ischemic-like conditions in the hippocampus. Sperlágh B; Zsilla G; Baranyi M; Illes P; Vizi ES Neuroscience; 2007 Oct; 149(1):99-111. PubMed ID: 17850981 [TBL] [Abstract][Full Text] [Related]
8. Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release. Ezeamuzie CI; Philips E Br J Pharmacol; 1999 May; 127(1):188-94. PubMed ID: 10369472 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists. Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033 [TBL] [Abstract][Full Text] [Related]
10. The role of intraspinal adenosine A1 receptors in sympathetic regulation. Peng SC; Ho CM; Ho ST; Tsai SK; Su CK Eur J Pharmacol; 2004 May; 492(1):49-55. PubMed ID: 15145705 [TBL] [Abstract][Full Text] [Related]
11. Probing Adenosine and P2 Receptors: Design of Novel Purines and Nonpurines as Selective Ligands. Jacobson KA Drug Dev Res; 2001; 52(1-2):178-186. PubMed ID: 38239932 [TBL] [Abstract][Full Text] [Related]
12. Repeated treatment with adenosine A1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene. De Sarro G; Donato Di Paola E; Falconi U; Ferreri G; De Sarro A Eur J Pharmacol; 1996 Dec; 317(2-3):239-45. PubMed ID: 8997606 [TBL] [Abstract][Full Text] [Related]